R. Koup, J. Safrit, and Y. Cao, Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome, J Virol, vol.68, pp.4650-4655, 1994.

P. Borrow, H. Lewicki, B. Hahn, G. Shaw, and M. Oldstone, Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection, J Virol, vol.68, pp.6103-6113, 1994.

A. Mcmichael and R. Sl, Cellular immune responses to HIV, Nature, vol.72, issue.6831, pp.980-987, 2001.
DOI : 10.1038/35073658

G. Freeman, E. Wherry, R. Ahmed, and A. Sharpe, Reinvigorating exhausted HIV-specific T cells via PD-1???PD-1 ligand blockade, The Journal of Experimental Medicine, vol.203, issue.10, pp.2223-2230, 2006.
DOI : 10.4049/jimmunol.175.3.1586
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118103

M. Lewis, M. Dagarag, B. Khan, A. Ali, and O. Yang, Partial Escape of HIV-1 from Cytotoxic T Lymphocytes during Chronic Infection, Journal of Virology, vol.86, issue.13, 2012.
DOI : 10.1128/JVI.06724-11

A. Saez-cirion, G. Pancino, M. Sinet, A. Venet, and O. Lambotte, HIV controllers: how do they tame the virus?, Trends in Immunology, vol.28, issue.12, pp.532-572, 2007.
DOI : 10.1016/j.it.2007.09.002

O. Lambotte, F. Boufassa, and Y. Madec, HIV Controllers: A Homogeneous Group of HIV-1--Infected Patients with Spontaneous Control of Viral Replication, Clinical Infectious Diseases, vol.41, issue.7, pp.1053-1059, 2005.
DOI : 10.1086/433188

A. Saez-cirion, C. Lacabaratz, and O. Lambotte, HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype, Proceedings of the National Academy of Sciences, vol.1, issue.4, pp.6776-81, 2007.
DOI : 10.1128/JVI.77.4.2550-2558.2003
URL : https://hal.archives-ouvertes.fr/pasteur-00142658

S. Migueles, C. Osborne, and C. Royce, Lytic Granule Loading of CD8+ T Cells Is Required for HIV-Infected Cell Elimination Associated with Immune Control, Immunity, vol.29, issue.6, pp.1009-1030, 2008.
DOI : 10.1016/j.immuni.2008.10.010

T. Miura, Z. Brumme, and M. Brockman, Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers, Journal of Virology, vol.84, issue.15, pp.7581-91, 2010.
DOI : 10.1128/JVI.00286-10

Z. Banki, W. Posch, and A. Ejaz, Complement as an Endogenous Adjuvant for Dendritic Cell-Mediated Induction of Retrovirus-Specific CTLs, PLoS Pathogens, vol.34, issue.15, p.1000891, 2010.
DOI : 10.1371/journal.ppat.1000891.s003

G. Tomaras, N. Yates, and P. Liu, Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia, Journal of Virology, vol.82, issue.24, pp.12449-63, 2008.
DOI : 10.1128/JVI.01708-08

B. Haynes, M. Moody, H. Liao, L. Verkoczy, and G. Tomaras, B cell responses to HIV-1 infection and vaccination: pathways to preventing infection, Trends in Molecular Medicine, vol.17, issue.2, pp.108-124, 2011.
DOI : 10.1016/j.molmed.2010.10.008
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3053087

K. Bar, H. Li, and A. Chamberland, Wide Variation in the Multiplicity of HIV-1 Infection among Injection Drug Users, Journal of Virology, vol.84, issue.12, pp.6241-6248, 2010.
DOI : 10.1128/JVI.00077-10

C. Moog, H. Fleury, I. Pellegrin, A. Kirn, and A. Aubertin, Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals, J Virol, vol.71, pp.3734-3775, 1997.

E. Gray, M. Moody, and C. Wibmer, Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual, Journal of Virology, vol.85, issue.15, pp.7719-7748, 2011.
DOI : 10.1128/JVI.00563-11

Y. Cao, L. Qin, L. Zhang, J. Safrit, and D. Ho, Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection, New England Journal of Medicine, vol.332, issue.4, pp.201-209, 1995.
DOI : 10.1056/NEJM199501263320401

D. Montefiori, G. Pantaleo, and L. Fink, Neutralizing and Infection-Enhancing Antibody Responses to Human Immunodeficiency Virus Type 1 in Long-Term Nonprogressors, Journal of Infectious Diseases, vol.173, issue.1, pp.60-67, 1996.
DOI : 10.1093/infdis/173.1.60

O. Lambotte, G. Ferrari, and C. Moog, Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers, AIDS, vol.23, issue.8, pp.897-906, 2009.
DOI : 10.1097/QAD.0b013e328329f97d
URL : https://hal.archives-ouvertes.fr/inserm-00387059

S. Heath, J. Tew, A. Szakal, and G. Burton, Follicular dendritic cells and human immunodeficiency virus infectivity, Nature, vol.377, issue.6551, pp.740-744, 1995.
DOI : 10.1038/377740a0

J. Jakubik, M. Saifuddin, D. Takefman, and G. Spear, Immune Complexes Containing Human Immunodeficiency Virus Type 1 Primary Isolates Bind to Lymphoid Tissue B Lymphocytes and Are Infectious for T Lymphocytes, Journal of Virology, vol.74, issue.1, pp.552-557, 2000.
DOI : 10.1128/JVI.74.1.552-555.2000
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC111570

V. Holl, M. Peressin, and T. Decoville, Nonneutralizing Antibodies Are Able To Inhibit Human Immunodeficiency Virus Type 1 Replication in Macrophages and Immature Dendritic Cells, Journal of Virology, vol.80, issue.12, pp.6177-81, 2006.
DOI : 10.1128/JVI.02625-05

D. Wilflingseder, Z. Banki, and E. Garcia, IgG Opsonization of HIV Impedes Provirus Formation in and Infection of Dendritic Cells and Subsequent Long-Term Transfer to T Cells, The Journal of Immunology, vol.178, issue.12, pp.7840-7848, 2007.
DOI : 10.4049/jimmunol.178.12.7840

M. Purtscher, A. Trkola, and G. Gruber, A Broadly Neutralizing Human Monoclonal Antibody against gp41 of Human Immunodeficiency Virus Type 1, AIDS Research and Human Retroviruses, vol.10, issue.12, pp.1651-1659, 1994.
DOI : 10.1089/aid.1994.10.1651

N. Casartelli, F. Guivel-benhassine, R. Bouziat, S. Brandler, O. Schwartz et al., The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells, The Journal of Experimental Medicine, vol.65, issue.1, pp.39-49, 2010.
DOI : 10.1038/nature01707
URL : https://hal.archives-ouvertes.fr/pasteur-00458098

A. Moris, C. Nobile, F. Buseyne, F. Porrot, J. Abastado et al., DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation, Blood, vol.103, issue.7, pp.2648-54, 2004.
DOI : 10.1182/blood-2003-07-2532
URL : https://hal.archives-ouvertes.fr/pasteur-01372698

E. Garcia, M. Pion, and A. Pelchen-matthews, HIV-1 Trafficking to the Dendritic Cell-T-Cell Infectious Synapse Uses a Pathway of Tetraspanin Sorting to the Immunological Synapse, Traffic, vol.97, issue.6, pp.488-501, 2005.
DOI : 10.1111/j.1600-0854.2005.00293.x

Z. Banki, L. Kacani, and P. Rusert, Complement dependent trapping of infectious HIV in human lymphoid tissues, AIDS, vol.19, issue.5, pp.481-487, 2005.
DOI : 10.1097/01.aids.0000162336.20439.8d

B. Heyman, The immune complex: possible ways of regulating the antibody response, Immunology Today, vol.11, pp.310-313, 1990.
DOI : 10.1016/0167-5699(90)90126-T

Y. Tanaka, S. Koido, M. Ohana, C. Liu, and J. Gong, Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells, The Journal of Immunology, vol.174, issue.3, pp.1274-80, 2005.
DOI : 10.4049/jimmunol.174.3.1274

S. Turley, K. Inaba, and W. Garrett, Transport of Peptide-MHC Class II Complexes in Developing Dendritic Cells, Science, vol.288, issue.5465, pp.522-529, 2000.
DOI : 10.1126/science.288.5465.522

M. Lutz, N. Kukutsch, and A. Ogilvie, An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow, Journal of Immunological Methods, vol.223, issue.1, pp.77-92, 1999.
DOI : 10.1016/S0022-1759(98)00204-X

K. Rafiq, A. Bergtold, and R. Clynes, Immune complex???mediated antigen presentation induces tumor immunity, Journal of Clinical Investigation, vol.110, issue.1, pp.71-80, 2002.
DOI : 10.1172/JCI0215640
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151032

A. Regnault, D. Lankar, and V. Lacabanne, Fc?? Receptor???mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I???restricted Antigen Presentation after Immune Complex Internalization, The Journal of Experimental Medicine, vol.70, issue.2, pp.371-80, 1999.
DOI : 10.1084/jem.184.3.863

M. Carrington, O. Brien, and S. , Genotype on AIDS, Annual Review of Medicine, vol.54, issue.1, pp.535-51, 2003.
DOI : 10.1146/annurev.med.54.101601.152346

P. Goulder and D. Watkins, Impact of MHC class I diversity on immune control of immunodeficiency virus replication, Nature Reviews Immunology, vol.80, issue.8, pp.619-649, 2008.
DOI : 10.1038/nri2357

H. Streeck, J. Jolin, and Y. Qi, Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T Cells, Journal of Virology, vol.83, issue.15, pp.7641-7649, 2009.
DOI : 10.1128/JVI.00182-09

J. Andrieu and W. Lu, A dendritic cell-based vaccine for treating HIV infection: background and preliminary results, Journal of Internal Medicine, vol.7, issue.2, pp.123-154, 2007.
DOI : 10.1111/j.1365-2796.2006.01738.x

M. Mcelrath and B. Haynes, Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination, Immunity, vol.33, issue.4, pp.542-54, 2010.
DOI : 10.1016/j.immuni.2010.09.011

L. Picker, S. Hansen, and J. Lifson, New Paradigms for HIV/AIDS Vaccine Development, Annual Review of Medicine, vol.63, issue.1, pp.95-111, 2012.
DOI : 10.1146/annurev-med-042010-085643

S. Buchbinder, D. Mehrotra, and A. Duerr, Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial, The Lancet, vol.372, issue.9653, pp.1881-93, 2008.
DOI : 10.1016/S0140-6736(08)61591-3

M. Mcelrath, D. Rosa, S. Moodie, and Z. , HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case???cohort analysis, The Lancet, vol.372, issue.9653, pp.1894-905, 2008.
DOI : 10.1016/S0140-6736(08)61592-5

N. Flynn, D. Forthal, C. Harro, F. Judson, K. Mayer et al., Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection, J Infect Dis, vol.191, pp.654-65, 2005.

P. Pitisuttithum, P. Gilbert, and M. Gurwith, Randomized, Double???Blind, Placebo???Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV???1 Vaccine among Injection Drug Users in Bangkok, Thailand, The Journal of Infectious Diseases, vol.194, issue.12, pp.1661-71, 2006.
DOI : 10.1086/508748

S. Rerks-ngarm, P. Pitisuttithum, and S. Nitayaphan, Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand, New England Journal of Medicine, vol.361, issue.23, pp.2209-2229, 2009.
DOI : 10.1056/NEJMoa0908492

M. Mcelrath, Immune Responses to HIV Vaccines and Potential Impact on Control of Acute HIV???1 Infection, The Journal of Infectious Diseases, vol.202, issue.S2, pp.323-329, 2010.
DOI : 10.1086/655658